Patents by Inventor Frances Lynn

Frances Lynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and products for evaluating an immune response to a therapeutic protein
    Patent number: 11686734
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: June 27, 2023
    Assignee: BIOGEN MA INC.
    Inventors: Meena Subramanyam, Lakshimi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
    Publication number: 20210025900
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
    Type: Application
    Filed: July 7, 2020
    Publication date: January 28, 2021
    Inventors: Meena Subramanyam, Lakshimi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • Methods and products for evaluating an immune response to a therapeutic protein
    Patent number: 10705095
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: July 7, 2020
    Assignee: BIOGEN MA INC.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
    Publication number: 20180088127
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
    Type: Application
    Filed: June 7, 2017
    Publication date: March 29, 2018
    Applicant: Biogen MA Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • Methods and products for evaluating an immune response to a therapeutic protein
    Patent number: 9709575
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titer of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titer of untreated patients increased by the double of the standard deviation of this control antibody titer.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: July 18, 2017
    Assignee: Biogen MA Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • EXTENDED TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20150175703
    Abstract: Methods for extended treatment of multiple sclerosis are described.
    Type: Application
    Filed: December 5, 2014
    Publication date: June 25, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Michael Panzara, Frances Lynn, Martin Toal
  • METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
    Publication number: 20150071917
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
    Type: Application
    Filed: July 14, 2014
    Publication date: March 12, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • Methods and products for evaluating an immune response to a therapeutic protein
    Patent number: 8871449
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: October 28, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • EXTENDED TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20120276048
    Abstract: Methods for extended treatment of multiple sclerosis are described.
    Type: Application
    Filed: July 5, 2012
    Publication date: November 1, 2012
    Inventors: Michael Panzara, Martin Toal, Frances Lynn
  • METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
    Publication number: 20120195884
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
    Type: Application
    Filed: September 23, 2011
    Publication date: August 2, 2012
    Applicants: Biogen Idec MA Inc., Elan Pharmaceuticals, Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin Mcdaid Barbour, Julie Elizabeth Taylor
  • Methods and products for evaluating an immune response to a therapeutic protein
    Patent number: 8124350
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: February 28, 2012
    Assignees: Biogen Idec MA Inc., Elan Pharmaceuticals, Inc.
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin Mcdaid Barbour, Julie Elizabeth Taylor
  • Methods and Products for Evaluating an Immune Response to a Therapeutic Protein
    Publication number: 20090176256
    Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.
    Type: Application
    Filed: April 4, 2006
    Publication date: July 9, 2009
    Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
  • Extended Treatment of Multiple Sclerosis
    Publication number: 20090010926
    Abstract: Methods for extended treatment of multiple sclerosis are described.
    Type: Application
    Filed: August 18, 2005
    Publication date: January 8, 2009
    Inventors: Michael Panzara, Martin Toal, Frances Lynn